NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$28.35 With US$31.37 ...

Royal Bank of Canada restated their outperform rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report published ...

Highlights,Institutional firms have modified their holdings in Biohaven Ltd., contributing to shifts in stock ...

Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Biohaven in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now expects that ...

$BHVN insiders have traded $BHVN stock on the open market 8 times in the past 6 months. Of those trades, 8 have been purchases and 0 have been sales. Here’s a ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed” data ...

Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.